Phase II Study of Recombinant Anti-tumor and Anti-Virus Protein for Injection Plus Capecitabine in Treating Patients With Metastatic Colorectal Cancer After Failure of Standard Treatment
Phase of Trial: Phase II
Latest Information Update: 04 Aug 2017
Price : $35 *
At a glance
- Drugs Capecitabine (Primary) ; Novaferon (Primary)
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- 04 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016 as per ClinicalTrials.gov record.
- 04 Jan 2016 Planned primary completion date changed from 1 Nov 2015 to 1 Nov 2016 as per ClinicalTrials.gov record.
- 25 Aug 2015 Planned End Date changed from 1 Apr 2015 to 1 Dec 2015 as per ClinicalTrials.gov record.